COMUNICADO DE BAXTER HEALTHCARE S.A. (2)

(Continuación)

Benefits of ADVATE

The innovative technology used to process ADVATE eliminates the potential pathogen risk associated with the use of animal-and human-derived plasma protein additives.

ADVATE is convenient for patients to use because it is available in extra-high potency (1500 IU/vial) so there may be fewer vials to reconstitute compared to RECOMBINATE, with a smaller infusion volume (5 mL solvent), which could lead to shorter infusion times mfor patients. ADVATE comes packaged with a 10mL syringe, butterfly, 2 alcohol swabs, 2 plasters, a device for reconstitution and a patient-friendly package insert.

Low rates of inhibitor development have been observed in previously treated patients in ADVATE clinical trials.

Baxter has the capacity to ensure supplies of ADVATE based on current and anticipated future needs. ADVATE is processed by Baxter in its dedicated, state-of-the art, recombinant protein processing facility in Neuchâtel, Switzerland.

Please see full prescribing information for further information.

Baxter, ADVATE and RECOMBINATE are trademarks of Baxter International Inc. and its affiliates.

[1] Kasper CK. Concentrate safety and efficacy. Haemophilia, 2002, 8, p. 161.

[2] Update on West Nile Virus and Blood and Organ Donations, National Hemophilia Foundation, Medical Advisory #393.

[3] Farrugia A. Evolving perspectives in product safety for haemophilia. Haemophilia (2002), 8, pp. 236-243.

[4] MASAC Recommendation #141 Treatment of hemophilia and other bleeding disorders (revised March 2003). MASAC Treatment Recommendations, National Hemophilia Foundation, 2002

Source: Baxter Healthcare S.A.

Contact: U.S. Media: Cindy Resman, +1(847)-948-2815, Europe Media contacts: Hans Vanavermaete, Baxter, +32-2-650-17-03, Inge Boets, Porter Novelli, +32-2-413-03-40, Investor contact: Mary Kay Ladone, +1(847)-948-3371

(158649)